ARCH Ventures, a venture capital firm, and General Catalyst, an investment company, led a $203m Series A round in Paradigm, a healthcare technology company, with participation from F-Prime Capital, GV, LUX Capital, Mubadala Capital, Magnetic Ventures, and BrightEdge. “The clinical research and drug development process is failing the very people it’s meant to serve. Patients who might be best served with participation in a clinical trial often can’t get access or aren’t offered access to trials, research departments are chronically overburdened with significant barriers to entry created by trial complexity, and as a result sponsors’ study timelines continue to lengthen at higher cost. The system is broken, and the human cost of inaction is unacceptable. Paradigm is reimagining the entire drug development paradigm by upending the status quo and focusing on equitable access to clinical research at scale from the start,” Kent Thoelke, Paradigm CEO.